UNSPSC 51101633: Amprolium

This classification denotes an antiparasitic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95CO6N199Q. European Medicines Agency schedules Amprolium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05489MIG. Amprolium generally arises in the molecular formula C14H19CLN4.

The term AMPROLIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7.) AMPROLIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amprolium under HS 29335995 and SITC 51576. As of Q4 2014, AMPROLIUM remains the US FDA Preferred Term for this commodity. Amprolium bears US NLM identifiers UMLS ID C0002686 and NCI Concept Code C76388. SMILES: [N]1(CC2C(NC(NC2)CCC)N)C(CCCC1)C.

UNSPSC 51101633 Amprolium is a Commodity code that does not align with the recent state and local opportunities tagged under it. The four recent solicitations — for naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies, and generic pharmaceuticals through cooperative purchasing — address pharmaceutical products, medical supplies, and pharmacy program administration, none of which relate to amprolium, a livestock anticoccidial feed additive used in animal agriculture. The code appears to have been misapplied to these opportunities by issuing bodies during tagging, suggesting either a cataloging error or a broader pharmaceutical-taxonomy misclassification. State and local governments do not appear to be actively procuring amprolium itself under this code based on available recent records.

The opportunities posted under this code between January and June 2026 reflect actual demand for naloxone kits and drug deactivation systems (Seminole County, Florida; City of Tampa), pharmacy benefit program administration and direct-to-manufacturer relationships (Texas Health and Human Services Commission), and multi-state cooperative pharmaceutical purchasing (Minnesota Multistate Cooperative Purchasing Alliance). Issuing bodies include county health agencies, municipal fire departments, state health commissions, and cooperative purchasing alliances serving multiple jurisdictions. Geographic activity centers on Florida and Texas with multistate cooperative participation. Given the complete mismatch between the code's nominal scope and the opportunities posted against it, firms evaluating this code should expect little relevant activity for amprolium procurement and should verify code assignments in any formal solicitations before bidding.